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Abstract
Background: Vascular calcification and reduced bone density are prevalent in chronic kidney disease and linked to
increased cardiovascular risk. The mechanism is unknown. We assessed the relationship between vascular calcification,
femoral bone density and left ventricular mass in patients with stage 3 non-diabetic chronic kidney disease in a cross-
sectional observational study.
Methodology and Principal Findings: A total of 120 patients were recruited (54% male, mean age 55614 years, mean
glomerular filtration rate 50613 ml/min/1.73 m
2). Abdominal aortic calcification was assessed using lateral lumbar spine
radiography and was present in 48%. Mean femoral Z-score measured using dual energy x-ray absorptiometry was
0.6061.06. Cardiovascular magnetic resonance imaging was used to determine left ventricular mass. One patient had left
ventricular hypertrophy. Subjects with aortic calcification had higher left ventricular mass compared to those without
(56616 vs. 48612 g/m
2, P=0.002), as did patients with femoral Z-scores below zero (56615 vs. 49613 g/m
2, P=0.01). In
univariate analysis presence of aortic calcification correlated with left ventricular mass (r=0.32, P=0.001); mean femoral Z-
score inversely correlated with left ventricular mass (r=20.28, P=0.004). In a multivariate regression model that included
presence of aortic calcification, mean femoral Z-score, gender and 24-hour systolic blood pressure, 46% of the variability in
left ventricular mass was explained (P,0.001).
Conclusions: In patients with stage 3 non-diabetic chronic kidney disease, lower mean femoral Z-score and presence of
aortic calcification are independently associated with increased left ventricular mass. Further research exploring the
pathophysiology that underlies these relationships is warranted.
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Introduction
Cardiovascular morbidity and mortality are increased in patients
withchronickidneydisease(CKD)andhaveanindependentinverse
relationship with glomerular filtration rate (GFR) [1]. There is
accumulating evidence that much of this increased risk is due to
underlying structural heart disease, such as left ventricular
hypertrophy (LVH), leading to arrhythmia and heart failure [2,3].
Left ventricular mass (LVM) assessed as a continuous variable is
increasingly recognised as an important prognostic marker [4], and
reductions in LVM are associated with improved outcome in
patients with increased cardiovascular risk [5].
Patients with CKD have deranged bone-mineral metabolism,
with increased levels of the phosphaturic hormone fibroblast
growth factor 23 (FGF-23) and parathyroid hormone (PTH)
arising from impaired renal excretion of phosphate and impaired
vitamin D activation [6]. Bone mineral density (BMD) measured
using dual-energy x-ray absorptiometry (DEXA) scanning is
commonly reduced in patients with CKD [7] and is an
independent predictor of cardiovascular mortality in dialysis
patients [8]. Vascular calcification is also highly prevalent in
CKD [9] and end stage kidney disease (ESKD) [10] and is
associated with increased mortality [11,12]. The mechanism by
which reduced BMD and vascular calcification might influence
cardiovascular outcome in CKD is unknown. We therefore
explored the relationship between femoral BMD, vascular
calcification and LVM, measured using the gold-standard
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39241technique of cardiovascular magnetic resonance imaging, in
a cohort of patients with stage 3 non-diabetic CKD.
Methods
Objectives
To determine the relationship between femoral bone density,
presence of vascular calcification and LVM in patients with stage 3
non-diabetic CKD.
Participants
Subjects were recruited from the renal clinics at the Queen
Elizabeth Hospital Birmingham, UK, from 2009 to 2011. Patients
were included if aged 18–80 years with stage 3 CKD (GFR 30–
59 mL/min/1.73 m
2) [13] and no change in medication in the
preceding three months. Patients with heart failure, atrial
fibrillation, moderate or severe valvular disease, uncontrolled
hypertension (office blood pressure .140/90 mmHg), total serum
cholesterol .5.5 mmol/L whether on or off treatment and
diabetes mellitus were excluded. Patients receiving treatment with
a phosphate binder or vitamin D analogue were also excluded.
Data collection
Demographic data including body mass index and heart rate
were recorded. Routine haematological and biochemical param-
eters were measured. Serum calcium levels were corrected for
serum albumin. GFR was estimated (eGFR) using the four-
variable Modification of Diet in Renal Disease formula with serum
creatinine recalibrated to be traceable to an isotope derived mass
spectroscopy method [14]. High sensitive C-reactive protein
(hsCRP) was measured using a validated immunoassay (IBL
International GMBH, Hamburg, Germany). Albuminuria was
measured using a spot albumin: creatinine ratio. Calcium-
phosphate homeostasis was assessed through measurement of the
phosphatonin FGF-23, its soluble co-receptor klotho, and vitamin
D. Fibroblast growth factor 23 was measured using a two-site
enzyme-linked immunosorbent assay (Kainos Laboratories Inc.,
Tokyo, Japan). Soluble serum a-klotho was determined using
a solid phase sandwich immunoassay (Immuno-Biological Labo-
ratories Co., Japan). 1,25-dihydroxyvitamin D was measured using
immunoextraction followed by quantitation by immunoassay
(Immunodiagnostic Systems Ltd, Tyne and Wear, UK). 25-
hydroxyvitamin D was measured by liquid chromatography-
tandem mass spectrometry. Urinary fractional excretion of
phosphate was calculated from 24-hour urine collections using
the equation [(urine phosphate x serum creatinine)/(urine
creatinine x serum phosphate)] x100, which allows correction for
incomplete urine collections over 24-hours and standardises
urinary phosphate excretion according to degree of renal
impairment [15]. Office brachial blood pressure (BP) was recorded
in the non-dominant arm in triplicate following 15 minutes of
supine rest using a validated oscillometric sphygmomanometer
(Dinamap ProCare 200, GE Healthcare, United Kingdom) [16]
according to British Hypertension Society guidelines [17]. All
subjects underwent twenty-four hour ambulatory BP measurement
(Meditech ABPM-04, PMS Instruments, Maidenhead, United
Kingdom). Arterial stiffness was assessed using the gold-standard
measurement of carotid-femoral pulse wave velocity (PWV,
SphygmoCor, AtCor Medical, Sydney) as previously described
using a high fidelity micromanometer (SPC-301, Millar Instru-
ments, Texas) to sequentially record electrocardiographically-
gated carotid and femoral waveforms following 15 minutes of
supine rest [18].
Assessment of bone density
Dual energy x-ray absorptiometry scanning (Hologic QDR
Series 4500 with Discovery Software version 11.02:03, Hologic
Europe, Zaventem, Belgium) was used to assess BMD of both
proximal femurs (femoral neck, Ward’s region, trochanteric
region). All scans were reported by an experienced bone
densitometry clinical scientist blinded to clinical data. T-scores
that refer to the young adult reference mean calculated from the
manufacturer’s database (based on the National Health and
Nutrition Examination Survey (NHANES) population) [19] were
determined. Osteopenia and osteoporosis were defined according
to the World Health Organisation definitions (normal bone T-
score .21, osteopenia T-score 21t o22.5 and osteoporosis T-
score ,22.5). The BMD of each subject was standardised by
calculating the difference between the observed and predicted
values (sourced from the manufacturer’s reference database based
on the NHANES population) [19] divided by the square root of
the estimated variance. This derived standard score, or Z-score, is
a measure of the deviation from the expected population mean,
adjusted for the covariance on a scale with zero mean and unit
standard deviation, so that 95% of the normal population will have
a Z-score between -2 and 2 [20]. Coefficients of variation in our
clinic are 1.1%.
Assessment of aortic calcification
The presence and extent of abdominal aortic calcification were
assessedusingalaterallumbarspineradiographandvalidatedsemi-
quantitativescoringmethodaspreviouslydescribed[21].Thissemi-
quantitative technique shows good correlation with electron beam
computed tomography assessment [22]. The abdominal aorta
adjacent to the L1-L4 vertebra was divided into four sections using
the midpoint of each intervertebral space as a boundary. The
anteriorandposterioraorticwallsofeachsectionwerescoredoutof
3 according to the extent of calcification present with a maximum
score of 24 for the entire abdominal aorta. All radiographs were
analysedandscoredbytwoindependentobservers.Anydiscordance
inthepresenceorabsenceofcalcificationbetweenthetwoobservers
resulted in re-assessment of that radiograph and evaluation by
a radiologist to reach a final consensus.
Cardiovascular magnetic resonance imaging
Cardiovascular magnetic resonance imaging was performed on
a 1.5 Tesla scanner (Symphony, Siemens, Erlangen, Germany).
Serial contiguous short axis cines were piloted from the vertical
long axis and horizontal long axis of the left ventricle (electrocar-
diographically-gated, steady-state free precession imaging [True-
FISP]; temporal resolution 40–50 ms, repetition time 3.2 ms, echo
time 1.6 ms, flip angle 60u, slice thickness 7 mm) in accordance
with previously validated methodologies [23]. Analysis was
performed offline (Argus Software, Siemens, Erlangen, Germany)
by a single observer for measurement of left ventricular function,
volumes and LVM [23], which was indexed to body surface area
(LVMI; Mosteller formula, BSA (m
2)= !((weight (kg) 6 height
(cm))/3600). Left ventricular hypertrophy was defined as an LVMI
greater than age and gender corrected limits [23].
Ethics
West Midlands Research Ethics Committee approved the study
and written informed consent was obtained from each participant.
The study was conducted in accordance with the Declaration of
Helsinki and the principles of Good Clinical Practice.
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All data were analysed using SPSS version 19 (SPSS Inc,
Chicago, Il, USA). Data are shown as mean6standard deviation,
frequency (percentage) or median (interquartile range). Data
distribution was tested using the Kolmogorov-Smirnov test and
normality plots. Normally distributed variables were analysed
using unpaired t-tests and x
2. Variables not normally distributed
were log transformed prior to analysis (serum triglycerides, hsCRP,
PTH, FGF-23, albumin-creatinine ratio, urinary fractional excre-
tion of phosphate and PWV). Analysis of variance with post hoc
Tukey was conducted to assess the impact of mean hip Z-score
and presence of vascular calcification on LVMI. Pearson
correlation and linear regression were used to assess the relation-
ship between two continuous variables. Colinearity between
variables was assessed by examining the variance inflation factor;
a value .5 indicated colinearity. A Type I error rate below 5%
(P,0.05) was considered statistically significant.
Reproducibility
Intraobserver variability for LVMI was determined by random
selection of twelve scans (10% of the cohort) for repeat analysis by
the same observer. Interobserver variability for aortic calcification
score was determined by comparing calcification scores between
two observers for all 120 subjects. Variability of LVMI and aortic
calcification score was determined using an intraclass correlation
coefficient and two-way random effects model.
Results
Participants
Of the 1297 patients with non-diabetic CKD screened in the
outpatient renal clinics, 602 met the study entry criteria. In total
494 patients were approached to take part in the CRIB-PHOS
Table 1. Demographic data for all subjects and according to presence or absence of abdominal aortic calcification.
All Patients Calcification No Calcification P
(n=120) (n=57) (n=63)
Age 55614 63611 47612 ,0.001
Males (%) 65 (54) 38 (67) 27 (43) 0.01
History of cardiovascular disease (%) 13 (11) 12 (21) 1 (2) 0.002
Smokers (%) 64 (53) 38 (68) 26 (41) 0.007
Body mass index (kg/m
2) 29.065.5 29.263.5 28.966.9 0.71
Office systolic blood pressure (mmHg) 128617 133617 123615 0.001
Office diastolic blood pressure (mmHg) 71611 71612 72610 0.61
Pulse pressure (mmHg) 57617 62619 52613 ,0.001
24-hour systolic blood pressure (mmHg) 124612 127612 121612 0.007
24-hour diastolic blood pressure (mmHg) 71697 0 687 2 69 0.19
24-hour pulse pressure (mmHg) 53611 57612 4968 ,0.001
Heart rate (bpm) 63610 62612 6369 0.82
Data are mean6standard deviation or frequency (%). Analysed using unpaired t-tests or x
2.
doi:10.1371/journal.pone.0039241.t001
Table 2. Renal diagnoses.
Renal Diagnosis Frequency (%)
Hypertensive nephropathy 16 (13)
IgA nephropathy 13 (11)
Reflux nephropathy 12 (10)
Adult polycystic kidney disease 12 (10)
Systemic vasculitis 13 (11)
Focal segmental glomerulosclerosis 8 (7)
Nephrectomy for neoplasm 5 (4)
Other glomerulonephritis 7 (6)
Other 30 (25)
Unknown 4 (3)
Data are frequency (percentage).
doi:10.1371/journal.pone.0039241.t002
Table 3. Medication use.
Medication Frequency (%)
ACEI 64 (53)
ARB 32 (27)
ACEI and/or ARB 92 (77)
Aspirin 23 (19)
Statin 53 (44)
Other lipid lowering therapy 6 (6)
b-blocker 20 (17)
Calcium-channel blocker 33 (28)
Diuretic 32 (27)
a-blocker 17 (14)
Calcium supplement 8 (7)
Bisphosphonate 9 (8)
Prednisolone 18 (15)
Immunosuppressant 23 (19)
Data are frequency (percentage). ACEI, angiotensin converting enzyme
inhibitor; ARB, angiotensin receptor blocker.
doi:10.1371/journal.pone.0039241.t003
Left Ventricular Mass and Chronic Kidney Disease
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39241study; 374 declined to participate and therefore 120 were
recruited. Demographic data for these 120 subjects are shown in
Table 1. The mean age of all participants was 55614 years with
54% male. Renal diagnoses and medication use are detailed in
Tables 2 and 3. Patients were on a mean of 1.761.2
antihypertensive agents with 77% receiving either an angiotensin
converting enzyme inhibitor and/or an angiotensin receptor
blocker. Biochemical data are shown in Table 4. Three per cent of
patients had a serum phosphate above 1.4 mmol/L, the upper
limit of normal for our assay. Thirty-six patients (32%) had a PTH
value above the upper limit of normal for our assay (65 ng/L) and
two had a PTH above twice the upper limit of normal. No patients
had a serum calcium concentration greater than 2.60 mmol/L.
Pulse wave velocity, left ventricular mass and bone density data are
shown in Table 5. Ten patients (8%) had osteopenia, of which six
were over the age of 50 years; no patients were overtly
osteoporotic. Ten patients (8%) had a Z-score of less than 21;
mean Z-score was 0.6061.06. Almost half (48%) of all participants
had detectable calcification of the aorta, with a median calcifica-
tion score of 4 (range 1–18). Only one patient (1%) had LVH.
Aortic calcification
A comparison of demographics between patients with calcifica-
tion and those without is shown in Table 1. Those with
calcification were significantly older, more likely to be male and
more likely to have a history of cardiovascular disease and smoking
compared to those without. The only biochemical differences were
higher serum triglycerides and higher serum calcium concentra-
tions in patients with aortic calcification; there was no difference in
serum phosphate, total cholesterol, hsCRP or eGFR (Table 4).
Table 4. Biochemical data for all subjects and according to presence or absence of abdominal aortic calcification.
All Patients Calcification No Calcification P
(n=120) (n=57) (n=63)
eGFR (mL/min/1.73m
2)5 0 613 48613 52613 0.09
Total cholesterol (mmol/L) 4.961.2 4.861.1 5.061.3 0.32
Triglycerides (mmol/L) 1.16 (0.84–2.00) 1.39 (0.98–2.15) 0.98 (0.73–1.40) 0.01
hsCRP (mg/mL) 2.21 (1.15–6.37) 3.02 (1.13–8.52) 1.96 (1.15–5.96) 0.54
Phosphate (mmol/L) 1.0360.16 1.0360.17 1.0360.17 0.98
Phosphate .1.4mmol/L (%) 4 (3) 2 (4) 2 (3) 1.00
Calcium (mmol/L) 2.2160.09 2.2360.09 2.1960.10 0.04
Parathyroid hormone (ng/L)
a 52 (38–71) 55 (42–72) 47 (35–71) 0.14
Parathyroid hormone .65ng/L (%)
a 36 (32) 18 (36) 18 (29) 0.54
Alkaline phosphatase (mmol/L) 182656 188658 177655 0.25
Fibroblast growth factor 23 (pg/mL) 67.6 (50.3–85.2) 67.0 (52.8–86.2) 67.6 (45.7–83.3) 0.34
Klotho (pg/mL) 943 6 396 951 6 471 936 6 317 0.84
1,25-dihydroxyvitamin D (pmol/L) 76.0 6 31.0 74.3 6 26.9 77.6 6 34.5 0.57
25-hydroxyvitamin D (nmol/L) 55.6 6 30.5 53.9 6 29.5 57.2 6 31.5 0.56
Albumin: creatinine ratio (mg/mmol) 6 (1–48) 8 (1–43) 3 (1–53) 0.86
Urinary fractional excretion of phosphate 21 (13–32) 19 (14–29) 21 (12–34) 0.74
aData available for 112 subjects. Data are mean6standard deviation, frequency (%) or median (interquartile range). Analysed using unpaired t-tests or x
2. eGFR,
estimated glomerular filtration rate; hsCRP, high sensitive C-reactive protein.
doi:10.1371/journal.pone.0039241.t004
Table 5. Arterial stiffness, left ventricular mass and bone mineral density data for all subjects and according to presence or
absence of abdominal aortic calcification.
All Patients Calcification No Calcification P
(n=120) (n=57) (n=63)
Pulse wave velocity (m/s) 8.9 (7.4–11.2) 10.0 (8.3–12.9) 8.0 (6.7–9.4) ,0.001
Pulse wave velocityadj (m/s) 9.1 (7.9–10.8) 10.4 (8.6–12.9) 8.2 (6.8–9.5) ,0.001
Left ventricular ejection fraction (%) 74677 5 687 4 66 0.20
Left ventricular mass (g) 101630 111630 93628 0.001
Left ventricular mass index (g/m
2)5 2 613 57614 48611 0.001
Mean femoral bone mineral density (g/cm
2) 1.0060.14 1.0260.14 0.9860.13 0.20
Mean femoral T-score 0.0360.96 0.0460.95 0.0260.98 0.89
Mean femoral Z-score 0.6061.06 0.7761.04 0.4561.06 0.10
Data are mean6standard deviation or median (interquartile range). Analysed using unpaired t-tests.
doi:10.1371/journal.pone.0039241.t005
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vitamin D. Individuals with calcification had stiffer arteries with
significantly higher PWV (10.0 (8.3–12.9) vs. 8.0 (6.7–9.4) m/s,
P,0.001) compared to those without (Table 5). Mean LVMI was
also higher in patients with calcification (57614 vs. 48611 g/m
2,
P=0.001). There was no significant difference in parameters of
femoral bone density between the groups.
Effects of bone density and vascular calcification on left
ventricular mass
Subjects were divided into two groups of high or low mean
femoral Z-score according to whether their mean femoral Z-score
wasaboveorbelowzero(thestandardisedmeanforthepopulation).
Patients in the high mean femoral Z-score group were older
(58612 vs. 45613 years, P,0.001), heavier (mean weight
87615 vs. 74614 kg, P,0.001) and had significantly lower LVMI
than those in the low Z-score group (50612 vs. 57615 g/m
2,
P=0.02). There were no other demographic or biochemical
differences between the groups; in particular there were no
significant differences in markers of bone metabolism or inflamma-
tion.Atwo-wayanalysisofvariancewasusedtoexploretheeffectof
high or low Z-scores and the presence or absence of aortic
calcification on LVMI. Both Z-score grouping and presence of
aortic calcification had significant effects on LVMI (P,0.001;
Figure 1).
Correlates of left ventricular mass
In univariate analyses mean femoral Z-score and presence of
aortic calcification correlated with LVMI (r=20.28, P=0.004
and r=0.32, P=0.001 respectively; Figure 2 and Table 6). All
variables that significantly correlated with LVMI in univariate
analyses were entered into a multiple regression model (Table 6),
with 24-hour systolic BP used as the most strongly correlated
variable for BP. The model explained 46% of the variability in
LVMI (P,0.001). Gender, 24-hour systolic BP, presence of aortic
calcification and mean femoral Z-score emerged as independent
predictors of LVMI, with systolic BP, presence of calcification and
mean femoral Z-score each contributing to 4% of the variation in
LVMI. Substitution of 24-hour systolic BP with office systolic BP
made no appreciable difference to the model.
Reproducibility
Intraobserver variability for LVMI was excellent with an
intraclass correlation coefficient of 0.992 (0.981–0.997,
P,0.001). Interobserver variability for aortic calcification was
also low with an intraclass correlation coefficient of 0.917 (0.883–
0.941, P,0.001).
Discussion
In this cross-sectional observational study of patients with stage
3 non-diabetic CKD a significant independent inverse relationship
between femoral bone density Z-scores and LVMI was demon-
strated. Furthermore, the presence of aortic calcification was
associated with increased aortic stiffness and significantly greater
LVMI independent of bone density. Our findings highlight
important links between bone disease, vascular calcification and
LVM, a prognostically important cardiovascular variable.
Several population studies have linked reduced bone density
and osteoporotic fractures with cardiovascular disease, especially
heart failure, although the mechanisms are unknown
[24,25,26,27]. Our findings suggest that underlying structural
heart disease may be an important link. The presence of LVH as
a marker of increased cardiovascular risk is well accepted, but the
value of LVM as a continuous variable that has a graded
relationship with cardiovascular risk is being increasingly recog-
nised [4,28]. Only one other study to date has demonstrated an
association between BMD and LVM. This cross-sectional study of
460 healthy individuals showed BMD to be an independent
predictor of echocardiographically-derived LVMI in post-meno-
pausal women but not in men [29].
Coronary artery calcification independently correlated with
LVMI in a study of 118 haemodialysis patients [30]. Most of the
patients in this study (75%) had established LVH on echocardi-
ography. Our data extends these findings to include patients with
early stage CKD, almost all of which had normal LVM. Vascular
calcification has been shown to be a predictor of adverse
cardiovascular outcome in several populations [11,12]. This has
Figure 1. The relationship between aortic calcification, mean
femoral Z-scores and left ventricular mass index. Both low mean
femoral Z-score (below zero) and presence of aortic calcification were
significantly associated with increased left ventricular mass index
(P,0.001, two-way analysis of variance).
doi:10.1371/journal.pone.0039241.g001
Figure 2. The relationship between mean femoral Z-score and
left ventricular mass index. Data analysed using Pearson correlation
(r
2=0.072, P=0.006).
doi:10.1371/journal.pone.0039241.g002
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also supports a contributory role for increased LVM.
Arterial stiffness is a powerful predictor of poor cardiovascular
outcome [12] and a number of studies, including our own, have
shown a relationship between vascular calcification and increased
arterial stiffness in CKD [31] and ESKD patients [32,33,34].
Increased arterial stiffness is characterised by augmented systolic
BP and pulse pressure, which can increase afterload on the left
ventricle, thus promoting ventricular stiffening, hypertrophy and
fibrosis [3]. Despite higher PWV in patients with calcification, we
did not demonstrate an association between arterial stiffness and
LVM. A relationship between arterial stiffness and LVMI has
previously been demonstrated in ESKD patients [35], but this is
not a consistent finding [36]. The near-normal PWV and LVM of
our cohort may have masked any potential underlying relationship
between these two variables.
Several reports from the general population have demonstrated
an inverse association between severity of vascular calcification
and bone density [37,38,39], with a similar relationship also being
reported in dialysis patients using coronary artery calcification
scoring [40,41]. Evidence of such a relationship in the early stage
CKD population is limited. In a cross-sectional analysis of 48
patients with CKD (mean GFR 35610 mL/min/1.73 m
2),
Toussaint et al demonstrated an inverse correlation between
femoral arterial calcification (but not aortic calcification) assessed
using computed tomography (CT) and femoral BMD measured
using DEXA scanning [31]. Filgueira et al divided 72 patients with
stage 2–4 CKD into tertiles of vertebral bone density measured
using CT and found those in the lowest bone density tertile to have
significantly higher coronary artery calcification than those in the
other tertiles [42]. In our study we did not demonstrate
a relationship between bone density and presence or extent of
vascular calcification. These differences may be explained by our
exclusion of diabetic patients, the relative absence of established
renal bone disease and relatively preserved kidney function in our
cohort (mean GFR 50613 mL/min/1.73 m
2) together with our
use of a less sensitive semi-quantitative technique for detection of
vascular calcification.
Abnormalities of mineral metabolism, such as elevated serum
phosphate and calcium-phosphate product, have been identified as
risk factors for the presence or progression of vascular calcification
in CKD patients in a number of studies [41], but this finding is not
consistent [9,31]. Similarly FGF-23 has been linked to calcification
of peripheral arteries but not of the aorta [43]. Serum calcium and
triglycerides were higher amongst patients with calcification in our
cohort but there were no significant differences in serum
phosphate, PTH, FGF-23, klotho, vitamin D, cholesterol or
alkaline phosphatase between groups. Our study does not support
a role for FGF-23, klotho or vitamin D as a mediator of increased
LVM in the setting of vascular calcification and reduced bone
density, but this requires confirmation with larger numbers of
patients. Serum levels of calcium and phosphate are poor markers
of total body calcium and phosphate content, and the prevalence
of hyperphosphataemia amongst our cohort was low, most likely
reflecting relatively preserved kidney function.
Limitations
Our study was observational and cross-sectional in design and
thus subject to potential confounding from missing variables. We
can only report associations and not infer causality. The use of
lateral lumbar spine radiography and a semi-quantitative scoring
method to assess severity of aortic calcification is not as sensitive as
other modalities such as CT scanning and is therefore likely to
have underestimated the prevalence of vascular calcification in our
cohort. Nevertheless we were still able to demonstrate an
independent relationship between severity of vascular calcification
and LVM using this method.
Conclusion
In patients with stage 3 non-diabetic CKD lower femoral bone
density Z-scores and presence of vascular calcification are
independently associated with increased LVM. Further studies
into the mechanisms and potential effect of treatments that
maintain bone density and attenuate progression of vascular
calcification on LVM are warranted.
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Mean femoral Z-score 20.28 0.004 20.23 24.75–
20.85
a24-hour systolic blood pressure was used as the strongest correlating variable
representing blood pressure in the model. Data analysed using Pearson
correlation (univariate) and enter linear regression (multivariate). All variables
that correlated significantly with left ventricular mass index in univariate
analysis were entered into the multivariate regression model. R
2 for
model=0.46, P,0.001. For gender 0=male, 1=female. b, standardised
coefficient; 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0039241.t006
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